hGHRH(1-44) vs Anamorelin
Head-to-head comparison of hGHRH(1-44) (Human growth hormone-releasing hormone (1-44) amide) and Anamorelin (Anamorelin hydrochloride (ONO-7643)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hGHRH(1-44) | Anamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Human growth hormone-releasing hormone (1-44) amide | Anamorelin hydrochloride (ONO-7643) |
| Molecular Weight | N/A | N/A |
| Half-Life | 5-15 minutes | about 9 hours |
| Amino Acids | 44 | N/A |
| Typical Dose | 0.1-1 mcg/kg | 50 mg/day |
| Route | Subcutaneous/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 95 |
| Research Status | Clinical Research | Clinical |
hGHRH(1-44) Benefits
- ✓physiologic GH pulse support
- ✓IGF-1 pathway stimulation
- ✓pituitary receptor mapping
- ✓endocrine research tool
Anamorelin Benefits
- ✓stimulates appetite
- ✓raises IGF-1
- ✓may support weight gain
- ✓oral dosing
hGHRH(1-44) Dosing
0.1-1 mcg/kg SC or IV bolus for stimulation studies|single-dose endocrine challenge with timed GH sampling|pulsatile administration in clamp/infusion experiments
Anamorelin Dosing
50 mg orally once daily|often studied with food or per protocol|track weight, appetite, and glucose markers
hGHRH(1-44) Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient nausea
Anamorelin Side Effects
- ⚠hyperglycemia
- ⚠peripheral edema
- ⚠constipation or nausea
Research Overview
hGHRH(1-44)
Human GHRH(1-44) amide has been used extensively to characterize hypothalamic control of pituitary somatotrophs and the downstream GH/IGF-1 axis. It remains a standard comparator in studies of GHRH agonism, secretion dynamics, and receptor pharmacology.
Anamorelin
Trials in cachexia populations showed increased appetite and modest gains in body weight and IGF-1. Regulatory progress has varied by region, but it remains a well-studied ghrelin agonist in the GH space.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.